Favorable prognosis of operable non-small cell lung cancer (NSCLC) patients harboring an increased expression of tumor endothelial markers (TEMs)

Lung Cancer

Volumn 81, Issue 2, 2013, Pages 252-258

  Pircher, Andreas ^a   Fiegl, Michael ^a   Untergasser, Gerold ^a   Heidegger, Isabel ^a   Medinger, Michael ^b   Kern, Johann ^a   Hilbe, Wolfgang ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Angiogenesis; Non small cell lung cancer (NSCLC); Prognostic factor; Robo4; Tumor endothelial cells

Indexed keywords

CD31 ANTIGEN; ENDOSIALIN; PROTEIN; PROTEIN ROBO4; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX DIFFERENCE; UPREGULATION;

ANGIOGENESIS; NON-SMALL CELL LUNG CANCER (NSCLC); PROGNOSTIC FACTOR; ROBO4; TUMOR ENDOTHELIAL CELLS;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; ENDOTHELIUM; EPITHELIAL CELLS; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, CELL SURFACE; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84879883224     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.04.014     Document Type: Article

References (32)

1. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
2. Salgia R. Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. Cancer 2011, 117:3889-3899.
3. Ulahannan S.V., Brahmer J.R. Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. Cancer Invest 2011, 29:325-337.
4. St Croix C.B., Rago C., Velculescu V., Traverso G., Romans K.E., Montgomery E., et al. Genes expressed in human tumor endothelium. Science 2000, 289:1197-1202.
5. Shi C., Lu J., Wu W., Ma F., Georges J., Huang H., et al. Endothelial cell-specific molecule 2 (ECSM2) localizes to cell-cell junctions and modulates bFGF-directed cell migration via the ERK-FAK pathway. PLoS ONE 2011, 6:e21482.
6. Verissimo A.R., Herbert J.M., Heath V.L., Legg J.A., Sheldon H., Andre M., et al. Functionally defining the endothelial transcriptome, from Robo4 to ECSCR. Biochem Soc Trans 2009, 37:1214-1217.
7. Seth P., Lin Y., Hanai J., Shivalingappa V., Duyao M.P., Sukhatme V.P. Magic roundabout, a tumor endothelial marker: expression and signaling. Biochem Biophys Res Commun 2005, 332:533-541.
8. Park K.W., Morrison C.M., Sorensen L.K., Jones C.A., Rao Y., Chien C.B., et al. Robo4 is a vascular-specific receptor that inhibits endothelial migration. Dev Biol 2003, 261:251-267.
9. Mehlen P., Delloye-Bourgeois C., Chedotal A. Novel roles for Slits and netrins: axon guidance cues as anticancer targets?. Nat Rev Cancer 2011, 11:188-197.
10. Zhang B., Dietrich U.M., Geng J.G., Bicknell R., Esko J.D., Wang L. Repulsive axon guidance molecule Slit3 is a novel angiogenic factor. Blood 2009, 114:4300-4309.
11. Mura M., Swain R.K., Zhuang X., Vorschmitt H., Reynolds G., Durant S., et al. Identification and angiogenic role of the novel tumor endothelial marker CLEC14A. Oncogene 2012, 31:293-305.
12. Yoder M.C., Mead L.E., Prater D., Krier T.R., Mroueh K.N., Li F., et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007, 109:1801-1809.
13. Steurer M., Kern J., Zitt M., Amberger A., Bauer M., Gastl G., et al. Quantification of circulating endothelial and progenitor cells: comparison of quantitative PCR and four-channel flow cytometry. BMC Res Notes 2008, 1:71.
14. Sterlacci W., Fiegl M., Hilbe W., Jamnig H., Oberaigner W., Schmid T., et al. Deregulation of p27 and cyclin D1/D3 control over mitosis is associated with unfavorable prognosis in non-small cell lung cancer, as determined in 405 operated patients. J Thorac Oncol 2010, 5:1325-1336.
15. Fiegl M., Hilbe W., Auberger J., Schmid T., Auberger J., Tzankov A., et al. Twelve-year retrospective analysis of lung cancer - The TYROL Study: daily routine in 1,424 patients (1995-2006). J Clin Oncol 2008, 26. (May 20 suppl; abstr 19063).
16. Sobin L., Wittekind D. UICC TNM classification of malignant tumors 2002, Wiley, New York. 6th ed.
17. Hilbe W., Dirnhofer S., Oberwasserlechner F., Schmid T., Gunsilius E., Hilbe G., et al. CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J Clin Pathol 2004, 57:965-969.
18. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:e45.
19. Siemann D.W. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents. Cancer Treat Rev 2011, 37:63-74.
20. Jones C.A., London N.R., Chen H., Park K.W., Sauvaget D., Stockton R.A., et al. Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability. Nat Med 2008, 14:448-453.
21. Jones C.A., Nishiya N., London N.R., Zhu W., Sorensen L.K., Chan A.C., et al. Slit2-Robo4 signalling promotes vascular stability by blocking Arf6 activity. Nat Cell Biol 2009, 11:1325-1331.
22. Chang P.H., Hwang-Verslues W.W., Chang Y.C., Chen C.C., Hsiao M., Jeng Y.M., et al. Activation of Robo1 signaling of breast cancer cells by Slit2 from stromal fibroblast restrains tumorigenesis via blocking PI3K/Akt/beta-catenin pathway. Cancer Res 2012, 72:4652-4661.
23. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL,et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathwaygenes. Nature 2012;491:399-405.
24. Wang B, Xiao Y, Ding BB, Zhang N, Yuan X, Gui L, et al. Induction of tumorangiogenesis by Slit-Robo signaling and inhibition of cancer growth by blockingRobo activity. Cancer Cell 2003;4:19-29.
25. Tseng RC, Lee SH, Hsu HS, Chen BH, Tsai WC, Tzao C, et al. SLIT2 attenuationduring lung cancer progression deregulates beta-catenin and E-cadherin andassociates with poor prognosis. Cancer Res 2010;70:543-51.
26. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005;5:436-46.
27. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell2011;144:646-74
28. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N EnglJ Med 2006;355:2542-50
29. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, et al.Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon:results of NSABP protocol C-08. J Clin Oncol 2011;29:11-6.
30. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastaticcolorectal cancer. N Engl J Med 2004;350:2335-42.
31. Seto T, Higashiyama M, Funai H, Imamura F, Uematsu K, Seki N, et al. Prognosticvalue of expression of vascular endothelial growth factor and its flt-1 and KDRreceptors in stage I non-small-cell lung cancer. Lung Cancer 2006;53:91-6.
32. Decaussin M, Sartelet H, Robert C, Moro D, Claraz C, Brambilla C, et al. Expressionof vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas